Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: events (609), actions (831), measures (541), trial (517), procedures (653), dealings (63), minutes (1000)

Remuneration and Appointment Committee ToR Feb 2023

Description: Remuneration and Appointment Committee Terms of Reference Date Issued: 28 February 2023 Review Date: February 2024 Document Typ
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Remuneration-and-Appointment-Committee-ToR-Feb-2023.pdf

Annual-report-2018-19

Description: ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Audit and Risk Committee ToR Jan 2023

Description: Audit and Risk Committee Terms of Reference Version: 5 Date Issued: Review Date: Document Type: 31 January 2023 January 2024
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2023.pdf

Axicel-Cyclophosphamide(500)-Fludarabine(30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Axicel-Cyclophosphamide500-Fludarabine30.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Remuneration and Appointment Committee ToR May 2022

Description: Remuneration and Appointment Committee Terms of Reference Date Issued: 26 May 2022 Review Date: November 2022 Document Type: Co
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Remuneration-and-Appointment-Committee-ToR-May-2022.pdf

RPMitCEBO-Bleomycin-Cyclophosphamide-Etoposide-Mitoxantrone-Prednisolone-Rituximab-Vincristine Ver 1.4

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-ETOPOSIDE-MITOXANTRONE-PREDNISOLONERITUXIMAB-VINCRISTINE (RPMitCEBO) Regimen  Lymphoma – RPMi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RPMitCEBO-Bleomycin-Cyclophosphamide-Etoposide-Mitoxantrone-Prednisolone-Rituximab-Vincristine-Ver-1.4.pdf

Audit and Risk Committee ToR Jan 2022

Description: Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Document Type: Committee T
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

HSCTAlemtuzumabFludarabineMelphalan-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GVHD) Volunteer Unrelated Donor (VUD) Conditioning This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-VUD-Methotrexate-GvHD.pdf

HSCTAlemtuzumabFludarabineMelphalan-Related_Methotrexate_GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GvHD) RELATED DONOR CONDITIONING This regimen will only be available to prescribe
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-Related-Methotrexate-GvHD.pdf

71 to 80 of 100

Previous … 6 7 8 9 10 Next